Compare Tempus AI (TEM) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs TG Therapeutics Inc — how do they compare? Tempus AI trades at $54.06 (market cap $10.05B), while TG Therapeutics Inc trades at $49.62 (market cap $7.64B). The key difference: Tempus AI is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| TEM | TGTX | |
|---|---|---|
Market Cap | $10.05B | $7.64B |
Sector | Broad Market / Factor | Health |
52-Week High | $103.25 | $59.06 |
52-Week Low | $41.55 | $26.94 |
Enterprise Value | $10.68B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $54.48, down 1.05% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported a Q2 2026 loss of $0.04 per share, beating estimates, and raised 2026 revenue guidance to $1.4 billion. Recent news highlights growth in oncology testing and AI-driven precision medicine, including the planned acquisition of Personalis to expand minimal residual disease testing capabilities.
Outlook remains positive with 61.5% analyst buy ratings and a $61.57 consensus price target, though risks include persistent net losses, high cash burn from operations, and competitive pressures in AI healthcare. The stock offers upside if execution improves profitability, but investors should monitor cash flow sustainability and integration of acquisitions.
TG Therapeutics (TGTX) trades at $49.66, up 1.02% on the day, with a bearish technical signal and recent earnings misses despite strong revenue growth. The company reported Q2 2026 revenue of $240 million and raised full-year BRIUMVI guidance to $950 million, but net income was impacted by manufacturing investments. Valuation ratios show a high P/E of 18.22 and EV/EBITDA of 56.26, while profitability metrics like ROE of 100.28% remain robust.
Outlook is mixed: strong product demand and raised revenue targets support growth, but earnings volatility and a bearish technical trend pose risks. Analyst consensus is bullish with an $63.75 price target, though legal investigations and competitive pressures require monitoring for stock investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
